Literature DB >> 2969357

Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2 receptor antagonist.

D B Jones1, C W Howden, D W Burget, C Silletti, R H Hunt.   

Abstract

The effects of a specific H2 receptor agonist impromidine, on gastric acid secretion were measured in six patients with duodenal ulcer in clinical remission before and after three months treatment with ranitidine 150 mg nocte. After treatment basal acid output increased from 1.2 to 2.8 mmol/h and after maximal impromidine stimulation from 36.9 (4.7) to 44.2 (6.2) mmol/h (p less than 0.02). Intravenous ranitidine 50 mg was given at the end of the impromidine infusion on each study day; the antisecretory effect of intravenous ranitidine was accentuated after the treatment with ranitidine from a trough acid output of 8.5 (1.2) mmol/h before, to 3.8 (1.5) mmol/h (p less than 0.05) after, treatment. The increased response to the H2 agonist impromidine and the H2 antagonist ranitidine after treatment with ranitidine suggests an enhanced sensitivity of the H2 receptor. This might be explained on the basis of an increase in the number of H2 receptors ('up-regulation').

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969357      PMCID: PMC1433767          DOI: 10.1136/gut.29.7.890

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  8 in total

1.  Definition and antagonism of histamine H 2 -receptors.

Authors:  J W Black; W A Duncan; C J Durant; C R Ganellin; E M Parsons
Journal:  Nature       Date:  1972-04-21       Impact factor: 49.962

2.  The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy.

Authors:  P J Prichard; D B Jones; N D Yeomans; G W Mihaly; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 3.  Histamine H2-receptor antagonists in the short- and long-term treatment of duodenal ulcer.

Authors:  J M Thomas; G Misiewicz
Journal:  Clin Gastroenterol       Date:  1984-05

4.  Prostaglandins for peptic ulcer disease.

Authors:  R H Hunt
Journal:  Lancet       Date:  1987-05-30       Impact factor: 79.321

5.  Impromidine (SK&F 92676) is a very potent and specific agonist for histamine H2 receptors.

Authors:  G J Durant; W A Duncan; C R Ganellin; M E Parsons; R C Blakemore; A C Rasmussen
Journal:  Nature       Date:  1978-11-23       Impact factor: 49.962

6.  Inhibition of acid secretion in dog by metiamide, a histamine antagonist acting on H2 receptors.

Authors:  M I Grossman; S J Konturek
Journal:  Gastroenterology       Date:  1974-04       Impact factor: 22.682

7.  The interaction of histamine with gastrin and carbamylcholine on oxygen uptake by isolated mammalian parietal cells.

Authors:  A H Soll
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

8.  Gastric secretory studies in humans with impromidine (SK&F 92676)--a specific histamine H2 receptor agonist.

Authors:  R H Hunt; J G Mills; J Beresford; J A Billings; W L Burland; G J Milton-Thompson
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

  8 in total
  10 in total

1.  Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.

Authors:  C U Nwokolo; J T Smith; A M Sawyerr; R E Pounder
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

2.  Antimuscarinic and anticholinesterase activity of cimetidine and ranitidine: clinically significant?

Authors:  M C Gwee; L S Cheah
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

3.  Tolerance to oral H2-receptor antagonists.

Authors:  C H Wilder-Smith; T Ernst; M Gennoni; B Zeyen; F Halter; H S Merki
Journal:  Dig Dis Sci       Date:  1990-08       Impact factor: 3.199

4.  Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.

Authors:  G M Fullarton; G McLauchlan; A Macdonald; G P Crean; K E McColl
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

5.  Can H2 -receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19-year-old female? A case report.

Authors:  Susan J Allen; Paul L Chazot; C Jane Dixon
Journal:  Br J Clin Pharmacol       Date:  2018-04-18       Impact factor: 4.335

Review 6.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

7.  Up-regulation of H2 receptor and adenylate cyclase in rabbit parietal cells during prolonged treatment with H2-receptor antagonists.

Authors:  K Takeuchi; M Kajimura; M Kodaira; S Lin; H Hanai; E Kaneko
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

8.  Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine.

Authors:  A F Kummer; D A Johnston; I N Marks; G O Young; N A Tigler-Wybrandi; S A Bridger
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

Review 9.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 10.  The H2-receptor antagonist era in duodenal ulcer disease.

Authors:  I N Marks
Journal:  Yale J Biol Med       Date:  1992 Nov-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.